Increased serum FSH in female fragile X premutation carriers with either regular menstrual cycles or on oral contraceptives

Human Reproduction

Volumn 16, Issue 3, 2001, Pages 457-462

  Hundscheid, Rubin D L ^a   Braat, Didi D M ^a   Kiemeney, Lambertus A L M ^a   Smits, Arie P T ^a   Thomas, Chris M G ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Diminished ovarian reserve; Fragile X premutation; FSH; Inhibin B; Premature ovarian failure

Indexed keywords

ESTRADIOL; ETHINYLESTRADIOL; FOLLITROPIN; INHIBIN B; ORAL CONTRACEPTIVE AGENT;

ADULT; AGE; ARTICLE; CONTROLLED STUDY; DISEASE CARRIER; DOSE RESPONSE; ENDOCRINE FUNCTION; FEMALE; FERTILIZATION IN VITRO; FOLLITROPIN BLOOD LEVEL; FRAGILE X SYNDROME; GENE MUTATION; GENETIC COUNSELING; GENETIC RISK; HETEROZYGOTE DETECTION; HUMAN; MAJOR CLINICAL STUDY; MENSTRUAL CYCLE; MULTIPLE REGRESSION; OVARY INSUFFICIENCY; PREGNANCY; PROGNOSIS; RISK FACTOR;

FALLOPIA;

EID: 0035104929     PISSN: 02681161     EISSN: None     Source Type: Journal    
DOI: 10.1093/humrep/16.3.457     Document Type: Article

References (25)

1. Fragile X premutation is a significant risk factor for premature ovarian failure: The International collaborative POF in fragile X study - Preliminary data
2. Menstrual disorders and endocrine profiles in fragile X carriers prior to 40 years of age
3. Pituitary and ovarian function in women receiving hormonal contraception
4. Further studies on pituitary and ovarian function in women receiving hormonal contraception
5. Inhibin-B as a test of ovarian reserve for infertile women
6. Laboratory criteria for menopause in women using oral contraceptives
7. Day 3 serum inhibin B and FSH and age as predictors of assisted reproduction treatment outcome
8. Effect of smoking on ovarian reserve and ovarian stimulation in in-vitro fertilization and embryo transfer
9. Quantitative comparison of FMR1 gene expression in normal and premutation alleles
10. Imprinting effect in premature ovarian failure confined to paternally inherited fragile X premutations
11. FMR1 and mutations in fragile X syndrome: Molecular biology, biochemistry, and genetics
12. The effect of age on the cyclical patterns of plasma LH, FSH, oestradiol and progesterone in women with regular menstrual cycles
13. Association between idiopathic premature ovarian failure and fragile X premutation
14. The effect of contraceptive steroids on hypothalamic-pituitary function
15. Serum concentration of follicle stimulating hormone may predict premature ovarian failure in FRAXA premutation women
16. Reproductive and menstrual history of females with fragile X expansions
17. Dimeric inhibin serum values as markers of ovarian activity in pill-free intervals
18. Expression of inhibin/activin subunits and follistatin messenger ribonucleic acids and proteins in ovarian follicles and the corpus luteum during the human menstrual cycle
19. Prognostic assessment of ovarian reserve
20. The detection of diminished ovarian reserve in infertile women
21. Assessment of unconjugated oestradiol and progesterone serum concentrations throughout pregnancy in normal women and in women with hyperprolactinaemia, who conceived after bromocriptine treatment
22. Premature ovarian failure (POF) and fragile X premutation females: From POF to fragile X carrier identification, from fragile X carrier diagnosis to POF association data
23. Gonadotropin and estradiol secretion during the week of placebo therapy in oral contraceptive pill users
24. Identification of a gene (FMR-1) containing a CGG repeat coincident with a breakpoint cluster region exhibiting length variation in fragile X syndrome
25. Female reproductive ageing is marked by decreased secretion of dimeric inhibin